Ovid says OV329 shows strong safety and efficacy in epilepsy
Ovid Therapeutics said OV329 demonstrated strong safety and efficacy in epilepsy and could address a roughly $1 billion market. It also said its KCC2 program, including a first-in-class oral KCC2 activator, is advancing toward key development milestones for schizophrenia and other CNS disorders.